0001104659-12-060483.txt : 20130103 0001104659-12-060483.hdr.sgml : 20130103 20120828163032 ACCESSION NUMBER: 0001104659-12-060483 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20120828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6173416100 MAIL ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 CORRESP 1 filename1.htm

 

 

 

 

VERTEX PHARMACEUTICALS INCORPORATED
130 WAVERLY STREET · CAMBRIDGE, MA 02139-4242
TEL. 617.444.6100 · FAX 617.444.7117
http://www.vrtx.com

 

 

August 28, 2012

 

Delivered via EDGAR

 

 

 

Securities and Exchange Commission

 

Division of Corporation Finance

 

100 First Street, N.E.

 

Mail Stop 4720

 

Washington, DC 20549

 

 

Attn:

Jim B. Rosenberg, Senior Assistant Chief Accountant

 

Lisa Vanjoske, Assistant Chief Accountant

 

James Peklenk, Staff Accountant

 

 

Re:

Vertex Pharmaceuticals Incorporated

 

Form 10-K for the Fiscal Year Ended December 31, 2011

 

Filed February 22, 2012

 

Form 10-Q for the Quarterly Period Ended March 31, 2012

 

Filed May 10, 2012

 

File No. 000-19319

 

 

Ladies and Gentlemen:

 

This letter relates to comments from the staff (the “Staff”) of the Securities and Exchange Commission to Vertex Pharmaceuticals Incorporated (the “Company”) set forth in the Staff’s letter to the Company, dated August 20, 2012 (the “Comment Letter”), regarding the above referenced Company filings.  As discussed with a representative of the Staff on August 23, 2012, the Company hereby confirms that the Company (i) has received the Comment Letter and (ii) will file its response to the Comment Letter on or before September 17, 2012.

 

Please contact me at 617-444-6227 in the event that you have any questions or concerns with respect to this matter.

 

 

Very truly yours,

 

 

 

/s/ Valerie L. Andrews

 

Valerie L. Andrews

 

Vice President and General Counsel

 

 GRAPHIC 2 g192911bci001.jpg GRAPHIC begin 644 g192911bci001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`****`"D)P**R_$>MQ:!HLU_+@LHVQ(?XW/04TKNR&E=V1QWQ&\52VUU!I M6G3%)8F6:9U/0CE5_J?PKL/#>MQ>(-&AOH\!R-LJ#^!QU%>%7$\MW M65BSL>Y-=)X#\1?V'K0@G?%G>$))GHK?PM_0_6NV=#]W9;HZYT?%;'`_.M/Q9I5SI%BNH6&J7PV. M%='G9LY[@UJJU1*R9JJLTK)F5_PJ:X_Z"\?_`'Y/^-'_``J:X_Z"\?\`WY/^ M-;.C:OJ>L>$;Q2SO>(XACE7@DMC!./3/6C6M)O\`1O#\MX-=U"6XBVY_>X3D M@'CKW]:?MZG]C/?+=1!MT6$*E M,]1UZ5@>%;6]U[3YY[G6]1C=)-B^7-QT!YS]:U[2SO;;P[JD-Q>7,D\4DACG M+D,0`"I%3*K.2LV3*I*2LSI:2O._!]QJ&N7TT5YJM]LCB#C9-@YSBNE.C7EM MJ]E/#J=[/;!SYT,LNX#Y3@_3-9D'045R/C&TU:U@.I:9?W21K_KX5D.`/[P_ MJ*;X&U]K^*6RO)WDNU)=6D;)=?;Z4`=A17([K[Q#XDD-A>W%OIEKB.62.0@3 M..H7^61722V7FQK&)YXP@P"DAS^)/6@##\=:9]MT$W"+F2T;S!Z[>C?X_A57 MX?:F)]*EL)'^:U.Y:=_-WL(XRV!@C^M`$/AF#6I/" MT1T^^MHE._8LD))!R>^?7VKI=%22/1;19@PE$0WANN[OFN?\-ZG)I&AQ6=UI M6I&6,L3LMR0MS:OJ2:%J<7]EP>:/,=3O)/\`#SP-OO5+5[:_G\72 MZA#873P)<(P<0M@A<<]/:NB\:Z%_:VGKJ%I&7N8!G`',B>F/44`;^E:7:Z18 MK:6BD(#DDG)8^IK.\:_\BI>?\`_]"%5?"&J7SVBV&IVMS')&,1321D!U]"?4 M58\:"6;P]);6\,DTLSJ`D:%C@')Z?2@#.^''_((NO^OC_P!E%=-J8_XE5W_U MP?\`]!-CW95'=FA955%+$DC`X M%`'GW@1+V34+D65Q%"X@&XR1[P1GZBNUT6'4HK[4#JVRRN/,N)HMH51R<>Y MQB@#HF4,A5@&!&"#WKR77;*/3=4FN-*>3[(LA19DR%1\^N>:`*OA+4K*_T: M);.-8#`H22`?P'U]P>N:W:\KL+37/#VMO+9V=Q<)$Y1BD9VS)G_/T->F6=VE MY;),J2)N'*2*593Z$&@">C%+10`E<[XL\6P^%X(3Y/VB>9OEBW;?E'5B:Z(U MXOX\D>?Q?>^:Q;RMJ("?NKM!Q^IK:C!3G9FM*"E*S-__`(6V_P#T!U_\"/\` MZU'_``MI_P#H#K_W_P#_`*U>>[%]*-B^E=OL*?8Z_8P['H7_``MI_P#H#C_P M(_\`K4?\+:?_`*`Z_P#@1_\`6KSW8OI1L7TH]A3[![&'8]"_X6T__0''_@1_ M]:C_`(6T_P#T!U_\"/\`ZU>>[%]*-B^E'L*?8/8P['H7_"VG_P"@./\`P(_^ MM1_PMI_^@.O_`($?_6KSW8OI1L7TH]A3[![&'8]"_P"%MO\`]`=?_`C_`.M0 MOQ:.X!]'PN1DB?)`_*O/=B^E&Q?2CV%/L'L8=CZ%M;F&]MHKF"0/%*@9&!Z@ JU-7%_"^:63P[+$[EDAN"L8/\(QG'YUVE>=*/+)HX9*SL&*,4M%22?__9 ` end